FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 01:06:17 10/05/2024 am IST | ||
| 0.35 EUR | -5.41% |
|
| 1 month | -18.60% | ||
| 3 months | -41.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/24/09 | 0.35 | -5.41% | 0 |
| 08/24/08 | 0.37 | +2.78% | 0 |
| 07/24/07 | 0.36 | -12.20% | 0 |
| 06/24/06 | 0.41 | -4.65% | 0 |
| 03/24/03 | 0.43 | +10.26% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 10, 2024 at 01:06 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SV23UV |
| ISIN | DE000SV23UV9 |
| Date issued | 06/04/2023 |
| Strike | 1,082 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.39 € |
|---|---|
| Lowest since issue | 0.29 € |
| Spread | 0.01 € |
| Spread % | 2.78% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
- Stock Market
- Certificates
- Certificat